

## Achieve to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 8, 2017 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference being held on November 28<sup>th</sup> and 29<sup>th</sup> at the New York Palace Hotel in New York City.



The Company's presentation will take place on Tuesday, November 28<sup>th</sup> at 1:30 PM EST in the Kennedy I room. A live webcast of the presentation can be accessed on the investor page of Achieve's website at <u>ir.achievelifesciences.com</u>. A replay of the webcast will also be archived on Achieve's website following the conference.

## **About Achieve & Cytisine**

Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisine. Tobacco use is currently the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide<sup>1</sup>. It is estimated that 28.6% of all cancer deaths in the U.S. are attributable to cigarette smoking<sup>2</sup>.

Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Two prior, large-scale Phase 3 clinical studies of cytisine, with favorable outcomes, have been successfully completed in over 2,000 patients. The TASC trial was a 740 patient, double-blind, placebo controlled trial conceived by Professor Robert West at University College London and funded by the U.K. National Prevention Research Initiative. The CASCAID trial was a 1,310 patient, single-blind, non-inferiority trial comparing cytisine to nicotine replacement therapy (NRT). The CASCAID trial was conceived by Dr. Natalie Walker, National Institute for Health Innovation, University of Auckland and funded by the Health Research Council of New Zealand. Both trials were published in the New England Journal of Medicine.

## **Achieve Contact**

Jason Wong jwong@bplifescience.com (415) 375-3340 ext. 4

View original content with multimedia: <a href="http://www.prnewswire.com/news-releases/achieve-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference-on-november-28th-2017-300551558.html">http://www.prnewswire.com/news-releases/achieve-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference-on-november-28th-2017-300551558.html</a>

SOURCE Achieve Life Sciences, Inc.

<sup>&</sup>lt;sup>1</sup> World Health Organization. WHO Report on the Global Tobacco Epidemic, 2011, Geneva: World Health Organization, 2011.

<sup>&</sup>lt;sup>2</sup> Annals of Epidemiology, Volume 25, Issue 3, 179 - 182.e1